Calcium channel blocking agents. Council on scientific affairs.
D000787:Angina Pectoris / Q000188:drug therapy; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001249:Asthma / Q000188:drug therapy; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy; D004110:Diltiazem / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D009203:Myocardial Infarction / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D014700:Verapamil / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine